Takeda announces positive results for mezagitamab in Phase 2 ITP study

Pallavi Madhiraju- March 14, 2024 0

Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab ... Read More